These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8277580)

  • 1. [Oral dyskinesis, facial dystonia].
    Nakamura S; Akiguchi I
    Nihon Rinsho; 1993 Nov; 51(11):2978-82. PubMed ID: 8277580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term evaluation of tiapride in patients with various forms of dyskinesia].
    Nakajima Y; Kondo T; Narabayashi H
    No To Shinkei; 1985 Oct; 37(10):1013-9. PubMed ID: 4074571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic characteristics of Meige dystonia: differentiation from tardive dyskinesia.
    Stahl SM; Yesavage JA; Berger PA
    J Clin Psychiatry; 1982 Nov; 43(11):445-6. PubMed ID: 7174619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects.
    Tolosa E; Martí MJ
    Adv Neurol; 1988; 49():73-84. PubMed ID: 3278555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a primate model for tardive dyskinesia.
    Bárány S; Häggström JE; Gunne LM
    Acta Pharmacol Toxicol (Copenh); 1983 Feb; 52(2):86-9. PubMed ID: 6846025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe tongue protrusion dystonia: clinical syndromes and possible treatment.
    Schneider SA; Aggarwal A; Bhatt M; Dupont E; Tisch S; Limousin P; Lee P; Quinn N; Bhatia KP
    Neurology; 2006 Sep; 67(6):940-3. PubMed ID: 17000958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involuntary movement disorders.
    Still CN
    Neurol Clin; 1984 Feb; 2(1):71-89. PubMed ID: 6239089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias.
    Stahl SM; Davis KL; Berger PA
    J Clin Psychopharmacol; 1982 Oct; 2(5):321-8. PubMed ID: 6127351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic stimulation of subthalamic nucleus elicits oral dyskinesia in rats.
    Parry TJ; Eberle-Wang K; Lucki I; Chesselet MF
    Exp Neurol; 1994 Aug; 128(2):181-90. PubMed ID: 7915675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms underlying levodopa-induced dyskinesia.
    Calabresi P; Di Filippo M; Ghiglieri V; Picconi B
    Mov Disord; 2008; 23 Suppl 3():S570-9. PubMed ID: 18781674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orofacial movement disorders.
    Balasubramaniam R; Ram S
    Oral Maxillofac Surg Clin North Am; 2008 May; 20(2):273-85, vii. PubMed ID: 18343330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bucco-linquo-facial and choriform hyperkinesies (author's transl)].
    Trillet M; Laurent B
    Sem Hop; 1978 Nov 8-15; 54(37-40):1159-63. PubMed ID: 33450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal involuntary movements: a study of dopaminergic receptor interaction.
    Agnoli A; Ruggieri S; Del Roscio S; Baldassarre M; Bocola V; Denaro A
    Adv Neurol; 1983; 37():305-12. PubMed ID: 6858777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reserpine: cause and treatment of oral-facial dyskinesia.
    Wolf SM
    Bull Los Angeles Neurol Soc; 1973 Apr; 38(2):80-4. PubMed ID: 4702802
    [No Abstract]   [Full Text] [Related]  

  • 18. [Neuroleptic-induced movement disorders: historical perspectives].
    Wolf MA; Yassa R; Llorca PM
    Encephale; 1993; 19(6):657-61. PubMed ID: 12404786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutical approach to involuntary movements (author's transl)].
    Allain H; Sabouraud O
    Sem Hop; 1979 Feb 8-15; 55(5-6):262-4. PubMed ID: 219537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients.
    Jankovic J; Ford J
    Ann Neurol; 1983 Apr; 13(4):402-11. PubMed ID: 6838174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.